ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
CAT No: R1806
CAS No:1135237-88-5
Synonyms/Alias:1135237-88-5;ADH-1 trifluroacetate;Exherin trifluoroacetate;Exherin (trifluoroacetate);ADH-1 trifluoroacetate;ADH-1 Peptide trifluroacetate;UNII-4OJ57R316O;4OJ57R316O;ADH-1 (trifluoroacetate);DTXSID10150444;(4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide;2,2,2-trifluoroacetic acid;L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-L-alanyl-L-valyl-, cyclic (1-5)-disulfide trifluroacetate;Exherin TFA Salt;(Adh-1)c trifluoroacetate;DTXCID5072935;GLXC-10745;EX-A4068;HY-13541A;NSC729477;AKOS026750576;CS-3607;DA-63340;F85093;Q27260293;L-Cysteinamide, cyclic (1 5)-disulfide, trifluoroacetate (salt) hydrate;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.